These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25908259)

  • 1. Neuritogenic militarinone-inspired 4-hydroxypyridones target the stress pathway kinase MAP4K4.
    Schröder P; Förster T; Kleine S; Becker C; Richters A; Ziegler S; Rauh D; Kumar K; Waldmann H
    Angew Chem Int Ed Engl; 2015 Oct; 54(42):12398-403. PubMed ID: 25908259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of selective 4-Amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization.
    Crawford TD; Ndubaku CO; Chen H; Boggs JW; Bravo BJ; Delatorre K; Giannetti AM; Gould SE; Harris SF; Magnuson SR; McNamara E; Murray LJ; Nonomiya J; Sambrone A; Schmidt S; Smyczek T; Stanley M; Vitorino P; Wang L; West K; Wu P; Ye W
    J Med Chem; 2014 Apr; 57(8):3484-93. PubMed ID: 24673130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors.
    Wang L; Stanley M; Boggs JW; Crawford TD; Bravo BJ; Giannetti AM; Harris SF; Magnuson SR; Nonomiya J; Schmidt S; Wu P; Ye W; Gould SE; Murray LJ; Ndubaku CO; Chen H
    Bioorg Med Chem Lett; 2014 Sep; 24(18):4546-4552. PubMed ID: 25139565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
    Reich SH; Sprengeler PA; Chiang GG; Appleman JR; Chen J; Clarine J; Eam B; Ernst JT; Han Q; Goel VK; Han EZR; Huang V; Hung INJ; Jemison A; Jessen KA; Molter J; Murphy D; Neal M; Parker GS; Shaghafi M; Sperry S; Staunton J; Stumpf CR; Thompson PA; Tran C; Webber SE; Wegerski CJ; Zheng H; Webster KR
    J Med Chem; 2018 Apr; 61(8):3516-3540. PubMed ID: 29526098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design.
    Han W; Ding Y; Xu Y; Pfister K; Zhu S; Warne B; Doyle M; Aikawa M; Amiri P; Appleton B; Stuart DD; Fanidi A; Shafer CM
    J Med Chem; 2016 Apr; 59(7):3034-45. PubMed ID: 27002243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based lead identification of ATP-competitive MK2 inhibitors.
    Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors.
    Yuan X; Wu H; Bu H; Zheng P; Zhou J; Zhang H
    Bioorg Med Chem; 2019 Apr; 27(7):1211-1225. PubMed ID: 30824167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and evaluation of highly selective pyridone-based class II MET inhibitors.
    She N; Zhuo L; Jiang W; Zhu X; Wang J; Ming Z; Zhao X; Cong X; Huang W
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3351-5. PubMed ID: 24951334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A unified approach for the stereoselective total synthesis of pyridone alkaloids and their neuritogenic activity.
    Jessen HJ; Schumacher A; Shaw T; Pfaltz A; Gademann K
    Angew Chem Int Ed Engl; 2011 Apr; 50(18):4222-6. PubMed ID: 21448865
    [No Abstract]   [Full Text] [Related]  

  • 10. Discovery of a novel series of potent MK2 non-ATP competitive inhibitors using 1,2-substituted azoles as cis-amide isosteres.
    Xiao D; Zhu X; Sofolarides M; Degrado S; Shao N; Rao A; Chen X; Aslanian R; Fossetta J; Tian F; Trivedi P; Lundell D; Palani A
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3609-13. PubMed ID: 24913714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
    Tsou HR; MacEwan G; Birnberg G; Zhang N; Brooijmans N; Toral-Barza L; Hollander I; Ayral-Kaloustian S; Yu K
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2259-63. PubMed ID: 20188551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
    Teo T; Yang Y; Yu M; Basnet SK; Gillam T; Hou J; Schmid RM; Kumarasiri M; Diab S; Albrecht H; Sykes MJ; Wang S
    Eur J Med Chem; 2015 Oct; 103():539-50. PubMed ID: 26408454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of c-Src kinase inhibitory activity of pyridin-2(1H)-one derivatives.
    Chand K; Prasad S; Tiwari RK; Shirazi AN; Kumar S; Parang K; Sharma SK
    Bioorg Chem; 2014 Apr; 53():75-82. PubMed ID: 24632506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.
    Goodman KB; Cui H; Dowdell SE; Gaitanopoulos DE; Ivy RL; Sehon CA; Stavenger RA; Wang GZ; Viet AQ; Xu W; Ye G; Semus SF; Evans C; Fries HE; Jolivette LJ; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Jung DK; Wright LL; Smith GK; Behm DJ; Bentley R; Doe CP; Hu E; Lee D
    J Med Chem; 2007 Jan; 50(1):6-9. PubMed ID: 17201405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
    Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
    ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
    Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel tetramic acids and pyridone alkaloids, militarinones B, C, and D, from the insect pathogenic fungus Paecilomyces militaris.
    Schmidt K; Riese U; Li Z; Hamburger M
    J Nat Prod; 2003 Mar; 66(3):378-83. PubMed ID: 12662096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety.
    Dow RL; Ammirati M; Bagley SW; Bhattacharya SK; Buckbinder L; Cortes C; El-Kattan AF; Ford K; Freeman GB; Guimarães CRW; Liu S; Niosi M; Skoura A; Tess D
    J Med Chem; 2018 Apr; 61(7):3114-3125. PubMed ID: 29570292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
    Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM
    J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
    Tsou HR; MacEwan G; Birnberg G; Grosu G; Bursavich MG; Bard J; Brooijmans N; Toral-Barza L; Hollander I; Mansour TS; Ayral-Kaloustian S; Yu K
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2321-5. PubMed ID: 20188552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.